Canaccord analyst William Plovanic lowered the firm’s price target on Staar Surgical to $79 from $88 and keeps a Buy rating on the shares. The analyst updated his estimates and said there are minimal changes to longer-term revenue and EPS estimates but his target is lowered due to comp group multiple compression.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on STAA:
